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Abstract
Background:  Micropapillary bladder cancer is a rare and aggressive variant of urothelial
carcinoma. A retrospective review of our experience in management of patients with muscle-
invasive or metastatic micropapillary bladder cancer was performed to better define the behavior
of this disease.
Methods: We reviewed the records of the 11 patients with micropapillary bladder cancer who
were evaluated and treated at Léon Bérard Cancer Center between 1994 and 2007, accounting for
1,2% of all urothelial tumors treated in this institution.
Results: Mean patients age was 60 years. The majority of patients (72%) were diagnosed after
2004. After a median follow-up of 31.7 months, median overall survival was 19 months. Two
patients presented with stage II, one with stage III and eight with stage IV disease All 5 patients who
had node positive metastases and treated with radical surgery and adjuvant chemotherapy relapsed
and had a disease free survival of 9.6 months.
Conclusion: Micropapillary bladder cancer is probably an underreported variant of urothelial
carcinoma associated with poor prognosis. Adjuvant chemotherapy might have a questionable
efficacy and the optimal treatment strategy is yet to be defined.
Background
Micropapillary bladder carcinoma is a rare variant of
urothelial bladder cancer recently described by Amin et al
[1], and accounting for 0,7 to 2,2% of all urothelial
tumors. It is associated with a rapid growth rate and an
advanced stage at presentation [1,2]. We retrospectively
analyzed 11 consecutive cases of muscle-invasive or met-
astatic micropapillary bladder cancer treated at the Léon
Bérard cancer center between 1994 and 2007 in order to
better define the behaviour of this aggressive disease.
Methods
We retrospectively searched the files of all patients with
muscle-invasive or metastatic micropapillary bladder car-
cinoma treated at the Léon Bérard cancer center between
1994 and 2007. Patients were considered to have micro-
papillary disease if the pathology report revealed any
micropapillary component (MPC) in their tumor. Patient
medical records were analyzed for demographic character-
istics, clinical stage and outcome. Radiology, pathology
and surgical reports were reviewed to determine the path-
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ological staging at the time of cystectomy using the 1997
TNM classification for genitourinary tumors [3]. Chemo-
therapy regimens, radiotherapy doses and surgical modal-
ity were also recorded. Overall survival was calculated
from the date of diagnosis to the date of death or the date
of last follow-up. Estimation of survival curves was per-
formed using the Kaplan-Meier technique.
Results
Characteristics of patients at initial presentation
Between 1994 and 2007, 911 patients with urothelial car-
cinoma were treated at the Léon Bérard cancer Center.
Eleven patients presented with muscle-invasive or meta-
static disease and had micropapillary features. Median age
at diagnosis was 60 years (48 to 76 years) and male/
female ratio was 9/1. Eighty percent of patients had previ-
ous smoking history. All patients had grade 3 urothelial
carcinoma and 35% had an associated in situ carcinoma.
One patient was diagnosed before year 2000, 1 in 2001, 1
in 2002 and 8 between 2004 and 2007. Two patients pre-
sented with stage II, one with stage III and eight with stage
IV disease. The average time between initial symptoms
and the beginning of treatment is 3,8 months, while this
period is 2 months for patients treated with surgery ini-
tially.
Treatment and outcome of patients with muscle invasive 
non metastatic disease
One patient had a cystoprostatectomy and pelvic lymph
node dissection. He was alive with no evidence of disease
recurrence two years after the diagnosis. The second
patient received concomitant pelvic chemoradiation at
the dose of 60 Grays. He relapsed 23 month later, received
subsequently two chemotherapy regimens and died ten
months later. The third patient refused treatment and died
8 months later.
Treatment and outcome of patients with metastatic 
disease
Seven patients had only regional lymph node metastases
while one had distant metastases. Among those seven
patients, six had cystoprostatectomy and pelvic lymph
nodes dissection of whom, five received 4 cycles of adju-
vant MVAC chemotherapy (methotrexate, vinblastin,
adriamycin and cisplatin). All of them relapsed and died
from metastases. One patient received four cycles of
MVAC chemotherapy and achieved a clinical complete
response. He had pelvic irradiation at the dose of 65 Grays
but died ten month later from disease progression. The
patient who presented with distant metastases was treated
with chemotherapy and died ten months after the initial
diagnosis.
Table S1 [see additional file 1] summarizes the initial
management of patients with muscle invasive or meta-
static micropapillary bladder cancer and table S2 [see
additional file 2] summarizes different chemotherapeutic
regimens used.
Metastatic sites
Ten out of the 11 patients developed distant metastases
during the follow up. The most frequent solid metastatic
site was the lung followed by liver and bone (Table S3 [see
additional file 3]).
Survival data
At a median follow up of 31.7 months, 9 patients have
died. Disease free survival was 9,6 months. One and two-
years survival were 64% and 36% respectively and median
survival was 19 months. Progression free survival is illus-
trated in figure 1 and overall survival in figure 2.
Discussion
Carcinoma with MPC was first described in 1982 as a var-
iant of endometrial carcinoma initially designed as papil-
lary serous carcinoma of the uterus [4]. Later, this subtype
was depicted in thyroid [5], breast [6], urinary tract [1]
and lung cancers [7].
Amin et al were the first to describe this entity in urothelial
carcinoma, in 1994. They identified two distinct morpho-
logic appearances. On the surface MPC are characterized
by small papillary tufts and slender, delicate processes,
often with a central fibrovascular core while in the inva-
sive part, the cells form small tight nests or balls often seen
within retracted connective tissue spaces [1]. Associated
typical urothelial carcinoma is usually high grade as was
shown in our series. Immunohistochemical profile typi-
cally shows CK7+/CK20+(CA125+/-) suggesting that it is
a form of glandular differentiation in urothelial carci-
noma [8,9].
Described less than 15 years ago, micropapillary bladder
cancer is likely underreported. In our institution, only 1
patient was diagnosed before year 2000 while the other 10
patients were identified between 2001 and 2007 mainly
after 2004 (8 cases). This suggests that the reported fre-
quency of micropapillary bladder cancer might increase in
the future as pathologists and oncologists become more
aware of its description and particular clinical behavior.
To date, there are no prospective trials in micropapillary
bladder cancer. Our retrospective study is the third largest
clinical series of muscle invasive and metastatic bladder
cancer reported in the literature after Kamat et al who
described 56 consecutive cases [10] and Johansson et al
who reported 17 consecutive cases [2]. The other relatively
large series are clinicopathological studies with no corre-
lation between treatment and outcome [1,8,11].BMC Urology 2009, 9:5 http://www.biomedcentral.com/1471-2490/9/5
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The presence of MPC in urothelial carcinoma was found
to be associated with an advanced stage of disease at the
time of presentation and an aggressive clinical course
[8,9,11,12]. In 2004, Samaratunga et al. [8] reported 20
cases of micropapillary bladder cancer and correlated the
pathological stage and prognosis with the extent and
extension of the micropapillary component on the
pathology specimen. In patients with superficial bladder
cancer, intravesical BCG was shown to be ineffective and
the authors concluded that the optimal treatment strategy
for non-invasive bladder cancer with micropapillary com-
ponents should be a radical cystectomy [13]. The same
authors stated in another study that in muscle invasive
surgically resectable disease, radical cystectomy should be
performed precociously. In this paper, the incidence of
pathologic upstaging was 52.7% and the incidence of
occult lymph node disease detected at the time of cystec-
tomy was 27.3%. Moreover patients undergoing neoadju-
vant chemotherapy were found to have a non-organ-
confined disease (³ T3) in 68% of cases compared to
patients treated with upfront surgery (34%) (p = 0,0157).
There was no survival benefit from the addition of neoad-
juvant chemotherapy and the authors recommended no
such approach especially in the absence of lymphovascu-
lar invasion [10]. Moreover, in this study, of the 15
patients with lymph node positive disease, 11 received
adjuvant chemotherapy after radical cystectomy, and only
5 were alive at the time of last follow-up (follow-up time
ranging from 29 to 42 months). This tends to show the
chemoresistant characters of micropapillary bladder can-
cer. In fact, in other organ sites, micropapillary carcinoma
appears to be less responsive to chemotherapy. For exam-
Disease free survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer Figure 1
Disease free survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer. Repre-
sents the Disease free survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer.
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ple, a retrospective study evaluated the pattern of chem-
oresistance in invasive micropapillary/low grade serous
ovarian carcinoma and high grade serous ovarian carci-
noma. Authors concluded that patients with recurrent
invasive micropapillary/low grade serous ovarian carci-
noma were more likely to manifest drug resistance to
standart chemotherapy agents (platinum and paclitaxel)
[14].
The present study showed occurrence of the disease in rel-
atively young patients (median age was 60 years) and an
associated poor prognosis. Patients who received multi-
modal treatment had a median disease free survival of 11
months and an overall survival of 21 months. All 5
patients with node positive disease who received surgery
followed by adjuvant MVAC regimen relapsed within a
median follow up of 20,2 months. This is in sharp con-
trast with other studies that used same treatment modali-
ties for node positive resected urothelial carcinoma [15-
18]. In the study by Stokle et al, only 3 among 11 patients
relapsed after a median follow-up period of 13.5 months
[15]. In the study by Freiha et al, 10 patients out of 18
relapsed after a median follow-up of 62 months [16]. This
further emphasizes on the aggressive character and chem-
oresistance of this variant of urothelial carcinoma.
Conclusion
Micropapillary bladder cancer is very likely an underre-
ported variant of urothelial carcinoma. It is associated
with a poor prognosis. The low incidence of this variant
Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer Figure 2
Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer. Description: 
represents the Overall survival of 11 patients with micropapillary muscle invasive or metastatic bladder cancer.
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renders the conduct of randomized trials rather impossi-
ble and drawing clear guidelines for its management is
subsequently difficult. Nevertheless, our series suggests
that adjuvant chemotherapy might have a questionable
efficacy especially in node positive disease, and the opti-
mal treatment modality remains to define.
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